Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.72 |
| ▸ | CA2 | P00918 | 6/20 | 0.72 |
| ▸ | CA9 | Q16790 | 2/20 | 0.72 |
| ▸ | CA12 | O43570 | 1/20 | 0.72 |
| ▸ | CA7 | P43166 | 1/20 | 0.72 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.72 |
| ▸ | PLK1 | P53350 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30938147 | 0.85 | CA1 (0.77) | CA1CA2CA9CA12CA7 | |
| SCHEMBL10603454 | 0.84 | CA1 (1.00) | CA1CA2CA9CA12CA7 | |
| SCHEMBL13233434 | 0.80 | PTPN7 (0.64) | CA1CA2CA9CA12CA7 | |
| SCHEMBL24169390 | 0.78 | ALDH1A1 (0.71) | ALDH1A1LMNAALOX12MEN1KMT2A | |
| SCHEMBL15335287 | 0.78 | PTPN7 (0.70) | CA1CA2CA9CA12PLK1 | |
| SCHEMBL15840804 | 0.77 | ALDH1A1 (0.75) | CA1CA2CA9ALDH1A1LMNA | |
| SCHEMBL18606699 | 0.76 | CA1 (0.76) | CA1CA2CA9PLK1ALDH1A1 | |
| SCHEMBL5432082 | 0.76 | PTPN7 (0.72) | CA1CA2CA9CA12PLK1 | |
| SCHEMBL3835013 | 0.76 | CA2 (0.68) | CA1CA2CA9CA12CA14 | |
| SCHEMBL18606712 | 0.75 | CA1 (1.00) | CA1CA2CA9CA12PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025073290-A1 | VPS4 INHIBITORS AND METHODS OF USE THEREOF | PARA THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | claimed |
| US-11858957-B2 | Ectonucleotidase inhibitors and methods of use thereof | ANTENGENT THERAPEUTICS LIMITED (CN) | 2024-01-02 | — | — | US | claimed |
| US-20230022922-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2023-01-26 | — | — | US | claimed |
| US-20220363709-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2022-11-17 | — | — | US | claimed |
| EP-3986894-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | Calithera Biosciences, Inc. (US) | 2022-04-27 | — | — | EP | claimed |
| CN-114008048-A | Exonucleotidase inhibitors and methods of use thereof | 卡利泰拉生物科技公司 | 2022-02-01 | — | — | CN | claimed |
| US-11208414-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2021-12-28 | — | — | US | claimed |
| US-11174261-B2 | — | — | 2021-11-16 | — | — | US | claimed |
| US-11034715-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2021-06-15 | — | — | US | claimed |
| EP-3810617-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | Calithera Biosciences, Inc. (US) | 2021-04-28 | — | — | EP | claimed |
| WO-2020257429-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2020-12-24 | — | — | WO | claimed |
| US-20200223882-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2020-07-16 | — | — | US | claimed |
| US-20200087310-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2020-03-19 | — | — | US | claimed |
| CN-110402249-A | Extracellular nucleotides enzyme inhibitor and its application method | CALITHERA BIOSCIENCES INC | 2019-11-01 | — | — | CN | claimed |
| EP-3558998-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | Calithera Biosciences, Inc. (US) | 2019-10-30 | — | — | EP | claimed |
| CN-110234656-A | Extracellular nucleotides enzyme inhibitor and its application method | 卡利泰拉生物科技公司 | 2019-09-13 | — | — | CN | claimed |
| EP-3510040-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | Calithera Biosciences, Inc. (US) | 2019-07-17 | — | — | EP | claimed |
| WO-2018119284-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2018-06-28 | — | — | WO | claimed |
| WO-2018049145-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2018-03-15 | — | — | WO | claimed |
| US-12630560-B2 | Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds | NUVALENT, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250382304-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250339412-A1 | METHODS OF TREATING SOLID TUMOR USING (19R)-5-CHLORO-3-ETHYL-16-FLUORO-10,19-DIMETHYL-20-OXA-3,4,10,11,23-PENTAAZAPENTACYCLO[19.3.1.02,6.08,12.013,18]PENTACOSA-1(24),2(6),4,8,11,13,15,17,21(25),22-DECAEN-22-AMINE | NUVALENT INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250326769-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12421273-B2 | Ectonucleotidase inhibitors and methods of use thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2025-09-23 | — | — | US | disclosed |
| EP-4605397-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | Nuvalent, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-4568969-A1 | HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | Nuvalent, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| US-12275742-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| WO-2025073290-A1 | VPS4 INHIBITORS AND METHODS OF USE THEREOF | PARA THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| WO-2025072120-A1 | HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | NUVALENT, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025072117-A1 | HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS AND ISOTOPOLOGUES THEREOF | NUVALENT, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| EP-4504736-A1 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | Nuvalent, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| EP-4504189-A1 | METHODS OF TREATING SOLID TUMOR USING (19R)-5-CHLORO-3-ETHYL-16-FLUORO-10,19-DIMETHYL-20-OXA-3,4,10,11,23-PENTAAZAPENTACYCLO[19.3.1.02,6.08,12.013,18]PENTACOSA-1(24),2(6),4,8,11,13,15,17,21(25),22-DECAEN-22-AMINE | Nuvalent, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20240398768-A1 | METHODS OF TREATING SOLID TUMOR USING HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | NUVALENT, INC. | 2024-12-05 | — | — | US | disclosed |
| US-20240352037-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. | 2024-10-24 | — | — | US | disclosed |
| US-20240327435-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. | 2024-10-03 | — | — | US | disclosed |
| US-20240317771-A1 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | NUVALENT, INC. | 2024-09-26 | — | — | US | disclosed |
| EP-3941481-B1 | COMPOSITIONS COMPRISING A PHOSPHORUS DERIVATIVE OF NICOTINAMIDE RIBOSIDE AND METHODS FOR MODULATION OF NICOTINAMIDE ADENINE DINUCLEOTIDE | METRO INT BIOTECH LLC (US) | 2024-09-18 | — | — | EP | disclosed |
| CN-118459485-A | Amino-substituted heterocycles for the treatment of cancers with EGFR mutations | 纽威伦特公司 | 2024-08-09 | — | — | CN | disclosed |
| EP-4408424-A1 | METHODS OF TREATING SOLID TUMOR USING HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | Nuvalent, Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| EP-4408844-A1 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | Nuvalent, Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| US-12054498-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-12043626-B2 | Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds | NUVALENT, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | NUVALENT, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2023196900-A9 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | NUVALENT, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20240132533-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENT THERAPEUTICS LIMITED (CN) | 2024-04-25 | — | — | US | disclosed |
| WO-2024086634-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-11939348-B2 | Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide | METRO INTERNATIONAL BIOTECH, LLC (US) | 2024-03-26 | — | — | US | disclosed |
| EP-4323356-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | Nuvalent, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-2024036098-A1 | HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | NUVALENT, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| WO-2024036097-A1 | HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS AND ISOTOPOLOGUES THEREOF | NUVALENT, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| CN-117500803-A | Amino-substituted heterocycles for the treatment of cancers with EGFR mutations | 纽威伦特公司 | 2024-02-02 | — | — | CN | disclosed |
| US-11858957-B2 | Ectonucleotidase inhibitors and methods of use thereof | ANTENGENT THERAPEUTICS LIMITED (CN) | 2024-01-02 | — | — | US | disclosed |
| WO-2022221227-A9 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20230322797-A1 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | CAMBREX CORPORATION | 2023-10-12 | — | — | US | disclosed |
| WO-2023196910-A1 | METHODS OF TREATING SOLID TUMOR USING (19R)-5-CHLORO-3-ETHYL-16-FLUORO-10,19-DIMETHYL-20-OXA-3,4,10,11,23-PENTAAZAPENTACYCLO[19.3.1.02,6.08,12.013,18]PENTACOSA-1(24),2(6),4,8,11,13,15,17,21(25),22-DECAEN-22-AMINE | NUVALENT, INC (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196900-A1 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | NUVALENT, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-11667649-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230124705-A1 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | NUVALENT, INC. | 2023-04-20 | — | — | US | disclosed |
| WO-2023056405-A1 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | NUVALENT, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023056431-A1 | METHODS OF TREATING SOLID TUMOR USING HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | NUVALENT, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20230107663-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. | 2023-04-06 | — | — | US | disclosed |
| EP-4146626-A2 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | Nuvalent, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-4146205-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | Nuvalent, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| US-20230076627-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. | 2023-03-09 | — | — | US | disclosed |
| CN-110234656-B | Exonucleotidase inhibitors and methods of use thereof | 卡利泰拉生物科技公司 | 2023-02-28 | — | — | CN | disclosed |
| US-20230022922-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2023-01-26 | — | — | US | disclosed |
| US-20230002437-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2023-01-05 | — | — | US | disclosed |
| US-11542278-B1 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220363709-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2022-11-17 | — | — | US | disclosed |
| US-20220363696-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. | 2022-11-17 | — | — | US | disclosed |
| US-20220340586-A9 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. | 2022-10-27 | — | — | US | disclosed |
| WO-2022221227-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| US-20220324899-A1 | COMPOUNDS AND COMPOSITIONS FOR DIFFERENTIAL MODULATION OF NICOTINAMIDE ADENINE DINUCLEOTIDE | METRO INTERNATIONAL BIOTECH, LLC | 2022-10-13 | — | — | US | disclosed |
| EP-4013766-A1 | COMPOUNDS AND COMPOSITIONS FOR DIFFERENTIAL MODULATION OF NICOTINAMIDE ADENINE DINUCLEOTIDE | Metro International Biotech, LLC (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20220144880-A1 | COMPOSITIONS COMPRISING A PHOSPHORUS DERIVATIVE OF NICOTINAMIDE RIBOSIDE AND METHODS FOR MODULATION OF NICOTINAMIDE ADENINE DINUCLEOTIDE | METRO INTERNATIONAL BIOTECH, LLC | 2022-05-12 | — | — | US | disclosed |
| WO-2022086892-A1 | INTERLEUKIN 4 (IL4)-INDUCED GENE 1 INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| EP-3986894-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | Calithera Biosciences, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20220098212-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT INC (US) | 2022-03-31 | — | — | US | disclosed |
| CN-114008048-A | Exonucleotidase inhibitors and methods of use thereof | 卡利泰拉生物科技公司 | 2022-02-01 | — | — | CN | disclosed |
| EP-3941481-A1 | COMPOSITIONS COMPRISING A PHOSPHORUS DERIVATIVE OF NICOTINAMIDE RIBOSIDE AND METHODS FOR MODULATION OF NICOTINAMIDE ADENINE DINUCLEOTIDE | Metro International Biotech, LLC (US) | 2022-01-26 | — | — | EP | disclosed |
| US-11208414-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11174261-B2 | — | — | 2021-11-16 | — | — | US | disclosed |
| WO-2021226208-A2 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021226269-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| US-11078228-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11034715-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| EP-3810617-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | Calithera Biosciences, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| WO-2021030551-A1 | COMPOUNDS AND COMPOSITIONS FOR DIFFERENTIAL MODULATION OF NICOTINAMIDE ADENINE DINUCLEOTIDE | METRO INTERNATIONAL BIOTECH, LLC (US) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021022258-A1 | TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF HEMATOLOGICAL CANCERS | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| WO-2020257429-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020197882-A1 | COMPOSITIONS COMPRISING A PHOSPHORUS DERIVATIVE OF NICOTINAMIDE RIBOSIDE AND METHODS FOR MODULATION OF NICOTINAMIDE ADENINE DINUCLEOTIDE | METRO INTERNATIONAL BIOTECH, LLC (US) | 2020-10-01 | — | — | WO | disclosed |
| US-20200223882-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2020-07-16 | — | — | US | disclosed |
| US-10618927-B1 | Compositions and methods for modulation of nicotinamide adenine dinucleotide | METRO INTERNATIONAL BIOTECH, LLC (US) | 2020-04-14 | — | — | US | disclosed |
| US-20200087310-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2020-03-19 | — | — | US | disclosed |
| US-10570167-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190389899-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2019-12-26 | — | — | US | disclosed |
| US-10472364-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| CN-110402249-A | Extracellular nucleotides enzyme inhibitor and its application method | CALITHERA BIOSCIENCES INC | 2019-11-01 | — | — | CN | disclosed |
| EP-3558998-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | Calithera Biosciences, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| CN-110234656-A | Extracellular nucleotides enzyme inhibitor and its application method | 卡利泰拉生物科技公司 | 2019-09-13 | — | — | CN | disclosed |
| EP-3510040-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | Calithera Biosciences, Inc. (US) | 2019-07-17 | — | — | EP | disclosed |
| US-20180186827-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2018-07-05 | — | — | US | disclosed |
| WO-2018119284-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018049145-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2018049145-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| US-20180072742-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (42 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132533-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | CA1 1237/4885CA2 356/4885CA9 724/4885 |
| US-20180186827-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | CA1 1237/4885CA2 356/4885CA9 724/4885 |
| US-20220363709-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | CA1 1237/4885CA2 356/4885CA9 724/4885 |
| US-20250326769-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | ROS1, MCL1, ALK | CA1 3740/4885CA2 2968/4885CA9 2808/4885 |
| US-20220144880-A1 | COMPOSITIONS COMPRISING A PHOSPHORUS DERIVATIVE OF NICOTINAMIDE RIBOSIDE AND METHODS FOR MODULATION OF NICOTINAMIDE ADENINE DINUCLEOTIDE | NAMPT, CD38, NADK | CA1 1932/4885CA2 409/4885CA9 1618/4885 |
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | EGFR, ERBB2, ERBB3 | CA1 4808/4885CA2 3966/4885CA9 1960/4885 |
| US-20240398768-A1 | METHODS OF TREATING SOLID TUMOR USING HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | VHL, PBRM1, NUP188 | CA1 235/4885CA2 330/4885CA9 79/4885 |
| US-20230022922-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | CA1 1237/4885CA2 356/4885CA9 724/4885 |
| US-11858957-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | CA1 1237/4885CA2 356/4885CA9 724/4885 |
| US-20200223882-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | CA1 1237/4885CA2 356/4885CA9 724/4885 |
| US-11034715-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | CA1 1237/4885CA2 356/4885CA9 724/4885 |
| US-11174261-B2 | — | ENTPD5, NT5E, ENTPD1 | CA1 1438/4885CA2 729/4885CA9 519/4885 |
| US-11208414-B2 | Ectonucleotidase inhibitors and methods of use thereof | ENTPD5, NT5E, ENTPD1 | CA1 1608/4885CA2 830/4885CA9 679/4885 |
| US-12421273-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | CA1 1237/4885CA2 356/4885CA9 724/4885 |
| US-20220098212-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | ABCB1, CYP2C8, PAICS | CA1 3182/4885CA2 3679/4885CA9 2068/4885 |
| US-12630560-B2 | Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds | CYP2F1, CYP11B2, CYP7B1 | CA1 1018/4885CA2 1093/4885CA9 237/4885 |
| US-20180072742-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | CA1 1237/4885CA2 356/4885CA9 724/4885 |
| US-20230124705-A1 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | CYP11B2, CYP4A11, CYP11B1 | CA1 1872/4885CA2 761/4885CA9 891/4885 |
| US-20240317771-A1 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | CYP11B2, CYP4A11, CYP11B1 | CA1 1872/4885CA2 761/4885CA9 891/4885 |
| US-10472364-B2 | Ectonucleotidase inhibitors and methods of use thereof | ENTPD5, NT5E, ENTPD1 | CA1 1608/4885CA2 830/4885CA9 679/4885 |
| US-12275742-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, PAICS | CA1 3509/4885CA2 4001/4885CA9 2346/4885 |
| US-11667649-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, PAICS | CA1 3509/4885CA2 4001/4885CA9 2346/4885 |
| US-20230076627-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | CYP2C8, ABCB1, PAICS | CA1 3509/4885CA2 4001/4885CA9 2346/4885 |
| US-10570167-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | CA1 1237/4885CA2 356/4885CA9 724/4885 |
| US-20250382304-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | CYP2C8, ABCB1, PAICS | CA1 3509/4885CA2 4001/4885CA9 2346/4885 |
| US-20250339412-A1 | METHODS OF TREATING SOLID TUMOR USING (19R)-5-CHLORO-3-ETHYL-16-FLUORO-10,19-DIMETHYL-20-OXA-3,4,10,11,23-PENTAAZAPENTACYCLO[19.3.1.02,6.08,12.013,18]PENTACOSA-1(24),2(6),4,8,11,13,15,17,21(25),22-DECAEN-22-AMINE | IL23R, IL17A, CA14 | CA1 196/4885CA2 966/4885CA9 43/4885 |
| US-20220363696-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | EGFR, ERBB2, ERBB4 | CA1 4776/4885CA2 3586/4885CA9 2326/4885 |
| US-10618927-B1 | Compositions and methods for modulation of nicotinamide adenine dinucleotide | NQO1, NADK, NAMPT | CA1 3440/4885CA2 1209/4885CA9 3059/4885 |
| US-12043626-B2 | Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds | CYP11B2, CYP4A11, CYP11B1 | CA1 1872/4885CA2 761/4885CA9 891/4885 |
| US-20230322797-A1 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | CYP11B2, CYP4A11, CYP11B1 | CA1 1872/4885CA2 761/4885CA9 891/4885 |
| US-20190389899-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | CA1 1237/4885CA2 356/4885CA9 724/4885 |
| US-20240352037-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | ABCB1, CYP2C8, PAICS | CA1 3292/4885CA2 3674/4885CA9 2483/4885 |
| US-11939348-B2 | Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide | NAMPT, CD38, NADK | CA1 1932/4885CA2 409/4885CA9 1618/4885 |
| US-11078228-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | CA1 1237/4885CA2 356/4885CA9 724/4885 |
| US-12054498-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, CYP3A43 | CA1 3189/4885CA2 3718/4885CA9 2221/4885 |
| US-20200087310-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | CA1 1237/4885CA2 356/4885CA9 724/4885 |
| US-11542278-B1 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, CYP3A43 | CA1 3189/4885CA2 3718/4885CA9 2221/4885 |
| US-20230107663-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | ABCB1, CYP2C8, PAICS | CA1 3292/4885CA2 3674/4885CA9 2483/4885 |
| US-20220324899-A1 | COMPOUNDS AND COMPOSITIONS FOR DIFFERENTIAL MODULATION OF NICOTINAMIDE ADENINE DINUCLEOTIDE | NQO1, NAMPT, NADK | CA1 4076/4885CA2 1456/4885CA9 3325/4885 |
| US-20230002437-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | CA1 1237/4885CA2 356/4885CA9 724/4885 |
| US-20240327435-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | EGFR, ERBB2, ERBB4 | CA1 4776/4885CA2 3586/4885CA9 2326/4885 |
| US-20220340586-A9 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | ABCB1, CYP2C8, PAICS | CA1 3182/4885CA2 3679/4885CA9 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.